Identification of the estrogen alpha receptor in normal endometrium and in clear cell carcinoma
Authors:
V. Šišovský 1; Ľ. Danihel 1; M. Palkovič 1; B. Bučeková 1; M. Redecha 2; M. Korbeľ 2; Z. Nižňanská 2; V. Repiská 3; A. Molnárová 4; I. Bartošová 5
Authors‘ workplace:
Ústav patologickej anatómie, Lekárska fakulta, Univerzita Komenského v Bratislave
1; 1. gynekologicko pôrodnícka klinika, Lekárska fakulta, Univerzita Komenského v Bratislave
2; Ústav lekárskej biológie, genetiky a klinickej genetiky, Lekárska fakulta, Univerzita Komenského v Bratislave
3; Oddelenie brachyterapie, Klinika radiačnej onkológie, Onkologický ústav sv. Alžbety, s. r. o., a SZU Bratislava
4; Interné oddelenie, Národný onkologický ústav, Bratislava
5
Published in:
Prakt Gyn 2009; 13(2): 106-109
Overview
Histomorphological appearance of endometrium and content of some proteins in it is changing in relation to a biological age of a woman. Important changes are arising mainly in tumour processes. In this work we focused on the expression of estrogen α receptor in clear cell endometrial carcinoma. We examined immunohistochemically 10 samples with normal proliferative endometrium and 10 samples with clear cell endometrial carcinoma. The expression of estrogen α receptor was high in proliferative endometrium. The expression of estrogen α receptor was not found in clear cell endometrial carcinoma that corresponded with worse clinical behaviour of the tumour. In conformity with other publications we are stating that the expression of this protein is an important prognostic marker of endometrial carcinoma. Therefore evaluation of this protein by immunohistochemistry is an important factor with implications for clinical practice.
Key words:
endometrial carcinoma – estrogen receptor – immunohistochemistry – prognostic marker
Sources
1. American Cancer Society. 2000 cancer statistics. CA Cancer J Clin 2000; 50(1): 1–64.
2. Ronnett BM, Zaino RJ, Ellenson LH et al. Endometrial Carcinoma. In: Kurman RJ. Blaustein`s Pathology of the Female Genital Tract. 5. ed. New York: Springer-Verlag 2002: 501–559.
3. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55(1): 10–30. Erratum in: CA Cancer J Clin 2005; 55(4): 259.
4. Pleško I, Vlasák V, Obšitníková A et al. Incidencia zhubných nádorov v Slovenskej republike v roku 1990. Bratislava: Národný onkologický ústav, Aktual klin Onkol 1994.
5. Pleško I, Vlasák V, Štefaňáková D et al. Incidencia zhubných nádorov v Slovenskej republike 2000. Bratislava: Národný onkologický ústav, Ústav experimentálnej onkológie SAV, Národný onkologický register Slovenskej republiky 2003.
6. Redecha M, Nižňanská Z, Korbeľ M. Výskyt zhubných nádorov tela maternice na Slovensku v rokoch 1990–2000. Gynekol prax 2004; 2(4): 194–199.
7. Mutter GL, Ferenczy A. Anatomy and histology of the uterine corpus. In: Kurman RJ. Blaustein`s Pathology of the Female Genital Tract. 5. ed. New York: Springer-Verlag 2002: 383–419.
8. Danihel Ľ, Porubský J. Prínos monoklonálnych protilátok v bioptickej diagnostike nádorov. Bratisl lek listy 1991; 92(9): 460–466.
9. Danihel Ľ, Babál P, Porubský J et al. Imunohistochemické markery v diagnostike nádorov maternice. Bratisl lek listy 1995; 96(7): 353–360.
10. Azumi N, Czernobilsky B. Immunohistochemistry. In: Kurman RJ. Blaustein`s Pathology of the Female Genital Tract. 5. ed. New York: Springer-Verlag 2002: 1251–1276.
11. Šišovský V. Imunohistochemická analýza endometria za fyziologických a patologických stavov. Dizertačná práca. Bratislava: Univerzita Komenského 2005.
12. Budaj M, Bučeková B, (Šišovský V, Danihel Ľ – školitelia). Identifikácia markerov proliferačnej aktivity v karcinóme endometria. 46. fakultná konferencia ŠVOČ. Zborník prác, Bratislava: LF UK a Slovak Academic Press 10. máj 2007: 22–25. (Práca ocenená diplomom dekana LF UK v Bratislave za prácu I. poradia, 1. miesto).
13. Budaj M, Bučeková B, (Šišovský V, Danihel Ľ, Repiská V – Mentors). Identification of proliferation markers in correlation with p53 gene mutation in endometrial carcinoma. Vědecká konference studentů českých a slovenských lékařských fakult. Program a abstrakta prednášek, Praha: 3. lékařská fakulta Univerzity Karlovy v Praze, 21.–22. listopad 2007.
14. Ondriaš F, Hrušovský A, Slugeň I et al. Mikroskopická diagnostika zmiešaných a mezenchýmových nádorov sliznice tela maternice. Bratisl lek listy 1990; 91: 551–558.
15. Ondriaš F. Zu routinemässigen gynekopathologischen bioptischen Utersuchungen und diagnostischen Problemen im Gebiet von Bratislava. Ber Path 1991; 113: 123–124.
16. Babál P, Slugen I, Daniš D et al. Sialic acid expression in normal and diseased human kidney. Acta Histochem 1996; 98(1): 71–77.
17. Sloboda J, Zaviačič M, Jakubovský J et al. Metastasizing adenocarcinoma of the female prostate (Skene‘s paraurethral glands). Histological and immunohistochemical prostate markers studies and first ultrastructural observation. Pathol Res Pract 1998; 194(2): 129–136.
18. Liang X, Lu B, Scott GK et al. Oxidant stress impaired DNA‑binding of estrogen receptor from human Brest cancer. Mol Cell Endocrinol 1998; 146(1–2): 151–161.
19. Henzl M. Patofyziologie ženských reprodukčních hormonů. In: Hulín I. Patofyziológia. 6. ed. Bratislava: Slovak Academic Press 2002: 1087–1097.
20. Marquez DC, Pietras RJ. Membrane‑associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001; 20(39): 5420.
21. Lax SF, Pizer ES, Ronnett BM et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29: 551–558.
22. Robboy SJ, Duggan MA, Kurman RJ. Gynecologic Pathology. In: Rubin E, Farber JL. Pathology. Philadelphia: J. B. Lippincott Company 1988: 942–989.
23. Gusberg SB. Detection and prevention of uterine cancer. Cancer 1988; 62: 1784–1786.
24. Redecha M, Korbeľ M, Sasko A. Histologické nálezy endometria pri krvácaní v klimaktériu a séniu. Prakt Gynek 1996; 3: 61–64.
25. Silverberg SG, Kurman RJ, Nogales F et al. Epithelial Tumors and Related Lesions In: Tavassoli FA, Devilee P. WHO classification of Tumours, Pathology and Genetics, Tumours of the Breast and Female Genital Organs. Tumours of the Uterine Corpus. Lyon: IARC Press 2003: 221–232.
26. Danihel Ľ, Horváth R, Breitenecker G et al. Súčasná klasifikácia a charakteristika nádorov endometria. Slov gynek por 2003; 10(Suppl 1): 14–17.
27. Danihel Ľ, Šišovský V, Palkovič M et al. Karcinóm endometria – histopatologická klasifikácia a charakteristika. Gynekol prax 2005; 3(1): 9–12.
28. Bokhman N. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10–17.
29. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular‑based classification. Virchows Arch 2004; 444(3): 213–223.
30. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007; 46(1): 6–32.
31. Redecha M, Nižňanská Z, Korbeľ M. Klinická charakteristika karcinómu endometria. Gynekol prax 2005; 3(1): 13–16.
32. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924–930.
33. Anderson MC, Robboy SJ, Russell P et al. Endometrial carcinoma. In: Robboy SJ, Anderson MC, Russell P. Pathology of the Female Reproductive Tract. London: Churchill Livingstone 2002: 331–359.
34. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985; 56(6): 1452–1455.
35. Sivridis E, Fox H, Buckley CH. Endometrial carcinoma – two or three entities? Int J Gynecol Cancer 1988; 183–188.
36. Bandera CA, Boyd J. The molecular genetics of endometrial carcinoma. In: Aldaz CM et al. Etiology of breast and Gynecological Cancers. Progres in Clinical and Biological Research. New York: Willey-Liss 1977: 185–203.
37. DakoCytomation 2004/05 Catalog. Denmark: Glostrup 2004.
38. Jakubovský J. Nekorektnosť vo vedeckom bádaní. In: Hulín I et al. Úvod do vedeckého bádania 1. Bratislava: Slovak Academic Press 2003: 424–442.
39. Mylonas I, Jeschke U, Shabani N et al. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER‑alpha), estrogen receptor beta (ER‑beta) and progesterone receptor (PR). Anticancer Res 2005; 25(3A): 1679–1686.
40. Saegusa M, Okayasu I. Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Jpn J Cancer Res 2000; 91(5): 510–518.
41. McCarty KSJ, Banon TK, Fetter BF et al. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol 1979; 96: 171–183.
42. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993; 50: 281–286.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2009 Issue 2
Most read in this issue
- Intrahepatic cholestasis of pregnancy and treatment with ursodeoxycholic acid.
- Pregnancy loss after the assisted reproductive technologies.
- Perioperative adhesion prevention in gynaecology.
- Thyroid cancer therapy with radioiodine 131I, the impact on gonadal functions and fertility.